Lifecore Biomedical, Inc. (LFCR) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, and thank you for joining LifeCore's Q3 2025 earnings call for the three months ended September 30th, 2025. During the call, all participants will be in a listen-only mode. Now I would like to turn the call over to Stephanie Diaz, Manager of Investor Relations for LifeCore. The floor is yours. Please pause one moment. We are experiencing some difficulties. Good afternoon and thank you for joining us today to discuss LifeCore Biomedical's third quarter 2025 earnings results. The three months ended September 30th, 2025. As we announced in August, the company has changed its fiscal year end to align with the calendar year. beginning with today's Q3 2025 results for the three months ended September 30th, 2025. We will be comparing our 2025 results to the closest comparable period in the prior year. Today, we will be comparing our Q3 2025 period for the three months ended September 30th, 2025 with the period ending August 25th, 2024. Going forward, our fiscal year end will end on December 31st, And we plan to announce results for Q4 and the approximately seven-month transition period from May 26th to December 31st, 2025 in March of 2026. Hosting the call today from LifeCorps are Paul Josephs, President and Chief Executive Officer, and Ryan Lake, Chief Financial Officer. Before we begin today, we'd like to remind everyone that certain statements made in the course of this conference call contain forward-looking statements. It is important to note that the forward-looking statements made during this call reflect management's judgment and analysis only as of today, November 6, 2025, and the company's actual results could differ materially from those projected in such forward-looking statements. For a more thorough discussion of the risks and uncertainties ass...